title: [Should bisphosphonate treatment be used for super-old patients with osteoporosis?].
authors.forename: Atsushi
authors.initials: A
authors.lastname: Harada
authors.forename: Seizo
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Kurato
authors.forename: Toshiki
authors.initials: T
authors.lastname: Iwase
authors.forename: Kikuo
authors.initials: K
authors.lastname: Inoue
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Takaaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Masaki
authors.initials: M
authors.lastname: Fujita
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nakano
authors.forename: Fujiko
authors.initials: F
authors.lastname: Ando
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*
chemical_list: D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; C008088:alfacalcidol; D019386:Alendronate